Polaris Partners

Polaris Partners is a venture capital firm founded in 1996 and headquartered in Boston, Massachusetts. With additional offices in San Francisco and New York, the firm specializes in investing across all stages of technology and healthcare companies, including life sciences and biotechnology. Polaris has established a strong track record over its more than 20 years in the industry, focusing on partnering with repeat entrepreneurs and innovators who are enhancing quality of life and work. The firm's investments are directed primarily within the United States and Europe, supporting companies from their founding stages to profitable growth.

William Allard

Venture Partner

Jonathan Ang

Entrepreneur Partner

Mark Augenstern

Associate

David Barrett

Managing Partner

David Barrett

Partner

Marissa Bertorelli

Principal

Mary Blair

CFO

Alexandra Cantley

Partner

Darren Carroll

Partner

Brian Chee

Managing Partner

Isaac Ciechanover

Partner

Alan Crane

Partner and Entrepreneur

Jon Flint

Founding Partner

Jonathan Flint

Founding Partner

Harold Friedman

CFO

John Gannon

CFO and Partner

Nil Gural

Senior Associate

Brendan Hannigan

Entrepreneur Partner

Rahul Kakkar

Entrepreneur Partner

Pat Kinsel

Partner

Scott Martin

Senior Associate

Eileen McGuire

Partner

Ellie McGuire

Partner

Terry McGuire

Founding Partner

Sabrina Chiasson

Principal

Pat Mulach

Senior Associate

Kim Png

Principal

Noel Ruane

Venture Partner

Jim Weinstein

Entrepreneur Partner

Past deals in Nanotechnology

Capstan Therapeutics

Series A in 2022
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Neumora

Series A in 2021
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Jnana Therapeutics

Series B in 2021
Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.

Amunix

Series B in 2021
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.

Neogene Therapeutics

Series A in 2020
Neogene Therapeutics, Inc. is a biotechnology company based in New York that focuses on the development of T cell therapies to treat cancer. Founded in 2018, the company specializes in creating personalized engineered T-cells that target neo-antigens, which are mutated proteins resulting from DNA alterations in cancer cells. Neogene's innovative platform allows for the isolation of T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies, which are routinely collected from patients. By utilizing advanced DNA sequencing and genetic screening technologies, Neogene can accurately identify and engineer TCRs that enhance the ability of T-cells to detect and eliminate cancer cells. This approach aims to improve treatment outcomes for cancer patients by providing therapies tailored to their unique tumor profiles.

Freenome

Series C in 2020
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Glympse Bio

Series B in 2020
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.

Amunix

Series A in 2020
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.

1366 Technologies

Series E in 2019
1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.

Faraday Pharmaceuticals

Series B in 2019
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.

Freenome

Series B in 2019
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Candesant Biomedical

Venture Round in 2019
Candesant Biomedical develops innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and headquartered in San Francisco, California, the company focuses on a proprietary medical device known as CDX-101. This non-invasive technology utilizes water-activated principles to deliver targeted energy to active sweat glands, effectively inactivating them without discomfort for patients. By controlling the interaction between alkali metals and water, Candesant's device aims to reduce excessive sweating and inhibit bacterial growth, providing a significant improvement in quality of life for individuals affected by this condition.

Glympse Bio

Series A in 2018
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.

Jnana Therapeutics

Series A in 2017
Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.

Suono Bio

Seed Round in 2017
Suono Bio, Inc. is focused on developing a novel platform technology for the rapid and localized delivery of therapeutic products, specifically targeting the gastrointestinal (GI) tract. Incorporated in 2016 and based in Medford, Massachusetts, the company aims to facilitate the administration of small molecules, proteins, vaccines, and nucleic acids without the need for encapsulation. Preclinical studies have shown the platform's effectiveness in delivering various therapeutics both locally and systemically, which supports its potential for treating inflammatory-mediated diseases. This innovative approach may offer significant advancements in therapeutic delivery, enhancing patient recovery from gastrointestinal conditions.

Freenome

Series A in 2017
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Neuronetics

Series G in 2017
Neuronetics is a medical technology company based in Malvern, Pennsylvania, established in 2003. It specializes in developing non-invasive therapies for psychiatric and neurological disorders, particularly Major Depressive Disorder (MDD). The company's flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to deliver MRI-strength magnetic pulses that induce electrical currents in targeted areas of the brain associated with mood regulation. This innovative treatment is the first of its kind to receive FDA clearance for patients who have not found relief from traditional antidepressant therapies. Neuronetics aims to improve the quality of life for individuals suffering from mental health conditions through its advanced, non-systemic treatment options.

Freenome

Series A in 2017
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Navitor Pharmaceuticals

Series B in 2015
Navitor Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing small molecule drugs that target mTORC1, a key regulator of cellular metabolism and renewal, to treat age-related diseases. Utilizing a proprietary platform, Navitor's therapies can selectively inhibit or activate mTORC1, which plays a crucial role in cellular processes. One of its notable products, NV-5138, is an orally bioavailable small molecule designed to activate mTORC1, particularly addressing its suppression in the brain associated with depression. Additionally, the company's N-Valog program focuses on selective inhibition of mTORC1 for chronic kidney disease, with implications for other age-related conditions. Founded in 2009 and headquartered in Cambridge, Massachusetts, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway by modulating nutrient-sensing proteins, thereby addressing various metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases.

Selecta Biosciences

Series E in 2015
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

Neuronetics

Series F in 2015
Neuronetics is a medical technology company based in Malvern, Pennsylvania, established in 2003. It specializes in developing non-invasive therapies for psychiatric and neurological disorders, particularly Major Depressive Disorder (MDD). The company's flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to deliver MRI-strength magnetic pulses that induce electrical currents in targeted areas of the brain associated with mood regulation. This innovative treatment is the first of its kind to receive FDA clearance for patients who have not found relief from traditional antidepressant therapies. Neuronetics aims to improve the quality of life for individuals suffering from mental health conditions through its advanced, non-systemic treatment options.

Novaerus

Venture Round in 2014
Novaerus's mission is to improve the business and quality of care through the application of airborne pathogen control technology. Novaerus believe that the preventative approach is the proper path to improved business and quality results in skilled nursing and assisted living facilities. Traditionally, important steps have been taken to clean hands and surfaces. Protocols exist on hand washing, surface cleaning and disinfectant and even isolation used as a tactic to prevent pathogens. When used in conjunction with these traditional methods, the Novaerus technology can go beyond just scrubbing hands and surfaces.

Selecta Biosciences

Private Equity Round in 2014
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

Faraday Pharmaceuticals

Series A in 2014
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.

Navitor Pharmaceuticals

Series A in 2014
Navitor Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing small molecule drugs that target mTORC1, a key regulator of cellular metabolism and renewal, to treat age-related diseases. Utilizing a proprietary platform, Navitor's therapies can selectively inhibit or activate mTORC1, which plays a crucial role in cellular processes. One of its notable products, NV-5138, is an orally bioavailable small molecule designed to activate mTORC1, particularly addressing its suppression in the brain associated with depression. Additionally, the company's N-Valog program focuses on selective inhibition of mTORC1 for chronic kidney disease, with implications for other age-related conditions. Founded in 2009 and headquartered in Cambridge, Massachusetts, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway by modulating nutrient-sensing proteins, thereby addressing various metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases.

1366 Technologies

Series C in 2013
1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.

Cerulean Pharma

Private Equity Round in 2012
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.

Infinite Power Solutions

Series D in 2012
Infinite Power Solutions, Inc. is a U.S.-based clean-technology company that specializes in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered near Denver, Colorado, IPS is recognized as a global leader in the production of innovative thin-film micro-energy cells, commonly known as thin-film batteries. The company has established the world's first volume manufacturing facility dedicated to these products and has recently initiated pre-production activities to meet the increasing demand across various sectors. IPS's thin-film batteries cater to a diverse range of microelectronic applications, including military and aerospace, smart cards, active RFID systems, implantable medical devices, and wireless sensors.

Cerulean Pharma

Series D in 2011
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.

Neuronetics

Series E in 2011
Neuronetics is a medical technology company based in Malvern, Pennsylvania, established in 2003. It specializes in developing non-invasive therapies for psychiatric and neurological disorders, particularly Major Depressive Disorder (MDD). The company's flagship product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to deliver MRI-strength magnetic pulses that induce electrical currents in targeted areas of the brain associated with mood regulation. This innovative treatment is the first of its kind to receive FDA clearance for patients who have not found relief from traditional antidepressant therapies. Neuronetics aims to improve the quality of life for individuals suffering from mental health conditions through its advanced, non-systemic treatment options.

1366 Technologies

Series B in 2010
1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.

Cerulean Pharma

Series C in 2010
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.

SIONYX

Series B in 2010
SiOnyx, Inc. is a company based in Beverly, Massachusetts, that specializes in the development and manufacturing of advanced light sensing devices. The firm has pioneered a patented semiconductor process known as shallow junction photonics, which significantly enhances the infrared sensitivity of silicon-based photonics. SiOnyx's product lineup includes ultra-low-light image sensors and HD action video cameras that facilitate digital night vision technology. These offerings cater to a diverse range of applications, including security, defense, consumer electronics, industrial use, medical fields, and automotive sectors. Incorporated in 2005, SiOnyx continues to lead in innovation, focusing on improving the performance of light sensing devices in both visible and near-infrared regions.

1366 Technologies

Series B in 2010
1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.

Infinite Power Solutions

Series C in 2010
Infinite Power Solutions, Inc. is a U.S.-based clean-technology company that specializes in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered near Denver, Colorado, IPS is recognized as a global leader in the production of innovative thin-film micro-energy cells, commonly known as thin-film batteries. The company has established the world's first volume manufacturing facility dedicated to these products and has recently initiated pre-production activities to meet the increasing demand across various sectors. IPS's thin-film batteries cater to a diverse range of microelectronic applications, including military and aerospace, smart cards, active RFID systems, implantable medical devices, and wireless sensors.

BIND Therapeutics

Series C in 2010
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

Selecta Biosciences

Series C in 2010
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

1366 Technologies

Series A in 2010
1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.

MicroCHIPS

Venture Round in 2010
MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.

Cerulean Pharma

Series B in 2009
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.

Selecta Biosciences

Series B in 2009
Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

Infinite Power Solutions

Series B in 2008
Infinite Power Solutions, Inc. is a U.S.-based clean-technology company that specializes in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered near Denver, Colorado, IPS is recognized as a global leader in the production of innovative thin-film micro-energy cells, commonly known as thin-film batteries. The company has established the world's first volume manufacturing facility dedicated to these products and has recently initiated pre-production activities to meet the increasing demand across various sectors. IPS's thin-film batteries cater to a diverse range of microelectronic applications, including military and aerospace, smart cards, active RFID systems, implantable medical devices, and wireless sensors.

Athenix

Series D in 2008
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

1366 Technologies

Series A in 2008
1366 Technologies Inc. is a manufacturer of silicon wafers primarily used in solar cell modules. Founded in 2007 and based in Bedford, Massachusetts, the company specializes in producing 3D direct wafers and traditional silicon solar wafers. Its innovative technology allows for the direct creation of silicon wafers from molten silicon, resulting in lower production costs, reduced energy requirements, and improved uniformity. This approach enables businesses to develop solar cells that offer a better price-to-performance ratio. 1366 Technologies has established strategic partnerships with Hanwha Q CELLS and operates additional locations in Shanghai, China, and Mumbai, India.

Cerulean Pharma

Series B in 2008
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.

Tempo Pharmaceuticals

Series B in 2008
Tempo Pharmaceuticals is a biotechnology company based in Madrid, Spain.

BIND Therapeutics

Series B in 2007
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

Cerulean Pharma

Series A in 2007
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.

BIND Therapeutics

Series A in 2007
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

Cerulean Pharma

Venture Round in 2006
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.

Infinite Power Solutions

Venture Round in 2006
Infinite Power Solutions, Inc. is a U.S.-based clean-technology company that specializes in the development, marketing, and manufacturing of solid-state, rechargeable thin-film micro-energy storage devices. Founded in 2001 and headquartered near Denver, Colorado, IPS is recognized as a global leader in the production of innovative thin-film micro-energy cells, commonly known as thin-film batteries. The company has established the world's first volume manufacturing facility dedicated to these products and has recently initiated pre-production activities to meet the increasing demand across various sectors. IPS's thin-film batteries cater to a diverse range of microelectronic applications, including military and aerospace, smart cards, active RFID systems, implantable medical devices, and wireless sensors.

Athenix

Series C in 2006
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

Nanosys

Series C in 2005
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.
Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.
Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.

Athenix

Series B in 2004
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

Alnylam Pharmaceuticals

Venture Round in 2003
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. Its innovative pipeline targets a range of serious conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system and ocular diseases. The company has successfully brought several RNAi therapeutics to market, including ONPATTRO for hereditary transthyretin-mediated amyloidosis and GIVLAARI for acute hepatic porphyria. Additionally, Alnylam is advancing other investigational therapies, such as givosiran for acute hepatic porphyria and lumasiran for primary hyperoxaluria type 1. The company collaborates with various partners, including Sanofi Genzyme and Vir Biotechnology, to enhance its research and development efforts. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals aims to transform treatment approaches for patients with rare and debilitating diseases through its RNAi technology.

Nanosys

Series B in 2003
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.

Acusphere

Funding Round in 2003
Acusphere, Inc. is a specialty pharmaceutical company based in Watertown, Massachusetts, focused on developing and commercializing cardiovascular drugs. Its primary product, Imagify, is an injectable suspension of perflubutane polymer microspheres used for evaluating myocardial perfusion and detecting coronary artery disease. The company is currently seeking regulatory approval for Imagify in Europe and is negotiating a Special Protocol Assessment with the FDA for an additional trial necessary for U.S. approval. Acusphere's proprietary porous microparticle technology has also facilitated the development of three other drugs in clinical trials: AI-525 for acute pain, AI-850 for oncology, and AI-128 for asthma. AI-525 and AI-850 were sold in transactions totaling $31 million, while AI-128 was developed in collaboration with Elan, which contributed $7.5 million to the program. Acusphere's technology holds promise for creating a diverse range of new drugs through the reformulation of hydrophobic compounds and the development of sustained-release formulations.

Advion

Series B in 2002
Advion is a global company headquartered in New York that specializes in the development of biochemistry analysis equipment. Founded in 1993, it offers a range of systems and consumables tailored for life science research. Advion's product portfolio includes chemist-centric mass spectrometers, nanoelectrospray ionization sources, and flow-chemistry synthesis systems. The company serves a diverse clientele comprising pharmaceutical firms, government life science research agencies, and academic institutions, focusing on the biopharmaceutical and industrial chemistry sectors.

Nanosys

Series A in 2002
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.

Nanosys

Seed Round in 2001
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.

Athenix

Series A in 2001
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.
Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.

Optobionics

Venture Round in 2000
Optobionics Corporation designs and develops artificial silicon retina (ASR) microchips for vision loss. Its ASR devices are used to stimulate damaged retinal cells. Optobionics Corporation was founded in 1990 and is based in Glen Ellyn, Illinois.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.